SOMMERFELD; Mark

Patent Applications and Registrations

Patent applications and USPTO patent grants for SOMMERFELD; Mark.The latest application filed is for "fgf21 variants".

Company Profile

4.7.19

SOMMERFELD; Mark - Frankfurt DE
SOMMERFELD; Mark - Frankfurt am Main DE
Sommerfeld; Mark - Bernsheim DE
SOMMERFELD; Mark - Bensheim DE
Sommerfeld, Mark - Korschenbroich DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Fgf21 Variants App 20220227825 - SOMMERFELD; Mark ; et al.	2022-07-21
FGF21 variants Grant 11,230,582 - Sommerfeld , et al. January 25, 2	2022-01-25
FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides App 20220010021 - SOMMERFELD; Mark ; et al.	2022-01-13
Fgf21 Compound / Glp-1r Agonist Combinations With Optimized Activity Ratio App 20200261542 - GOBEL; Britta ; et al.	2020-08-20
FGF21 compound / GLP-1R agonist combinations with optimized activity ratio Grant 10,583,174 - Gobel , et al.	2020-03-10
Fusion Proteins For Treating A Metabolic Syndrome App 20190085043 - Boscheinen; Oliver ; et al.	2019-03-21
Fgf21 Variants App 20180371041 - SOMMERFELD; Mark ; et al.	2018-12-27
Fgf21 Compound / Glp-1r Agonist Combinations With Optimized Activity Ratio App 20180236037 - GOBEL; Britta ; et al.	2018-08-23
Pharmaceutical Composition For Treating A Metabolic Syndrome App 20180236033 - Sommerfeld; Mark ; et al.	2018-08-23
Insulin derivatives having an extremely delayed time-action profile Grant 9,644,017 - Habermann , et al. May 9, 2	2017-05-09
Pharmaceutical Composition For Treating A Metabolic Syndrome App 20160279199 - Sommerfeld; Mark ; et al.	2016-09-29
Fusion proteins comprising FGF-21 and GLP-1R agonist App 20160194371 - Boscheinen; Oliver ; et al.	2016-07-07
Pharmaceutical Composition for Treating a Metabolic Syndrome App 20150231210 - SOMMERFELD; Mark ; et al.	2015-08-20
Pharmaceutical Composition for Treating A Metabolic Syndrome App 20140142023 - Sommerfeld; Mark ; et al.	2014-05-22
Fusion Proteins For Treating A Metabolic Syndrome App 20140073563 - BOSCHEINEN; Oliver ; et al.	2014-03-13
Insulin derivatives having an extremely delayed time-action profile Grant 8,633,156 - Habermann , et al. January 21, 2	2014-01-21
Pharmaceutical Composition For Treating A Metabolic Syndrome App 20130203651 - Sommerfeld; Mark ; et al.	2013-08-08
Novel Insulin Derivatives Having An Extremely Delayed Time-action Profile App 20110173722 - HABERMANN; Paul ; et al.	2011-07-14
Novel Insulin Derivatives Having An Extremely Delayed Time-action Profile App 20110077197 - HABERMANN; Paul ; et al.	2011-03-31
Method for identifying IRS inhibitors or agonists Grant 7,803,571 - Tennagels , et al. September 28, 2	2010-09-28
Method for the identification of IRS protein kinase inhibitors or agonist App 20050106653 - Tennagels, Norbert ; et al.	2005-05-19

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.